H. Nogai, B. Dörken, and G. Lenz, Pathogenesis of Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.29, issue.14, pp.1803-1811, 2011.
DOI : 10.1200/JCO.2010.33.3252

P. Bhende, S. Park, M. Lim, D. Dittmer, and B. Damania, The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma, Leukemia, vol.24, issue.10, pp.1781-1784, 2010.
DOI : 10.1073/pnas.1137463100

M. Desai, K. Newberry, J. Romaguera, L. Zhang, Z. Ou et al., Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy, Journal of Hematology & Oncology, vol.6, issue.1, p.55, 2013.
DOI : 10.1158/0008-5472.CAN-08-4898

I. Vivanco and C. Sawyers, The phosphatidylinositol 3-Kinase???AKT pathway in human cancer, Nature Reviews Cancer, vol.2, issue.7, pp.489-501, 2002.
DOI : 10.1038/nrc839

B. Jiang and L. Liu, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1784, issue.1, pp.19-65, 2009.
DOI : 10.1016/j.bbapap.2007.09.008

B. Vanhaesebroeck and M. Waterfield, Signaling by Distinct Classes of Phosphoinositide 3-Kinases, Experimental Cell Research, vol.253, issue.1, pp.239-254, 1999.
DOI : 10.1006/excr.1999.4701

J. Engelman, J. Luo, and L. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nature Reviews Genetics, vol.61, issue.8, pp.606-619, 2006.
DOI : 10.1073/pnas.84.14.5034

L. Cantley, The Phosphoinositide 3-Kinase Pathway, Science, vol.296, issue.5573, pp.1655-1657, 2002.
DOI : 10.1126/science.296.5573.1655

M. Osaki, M. Oshimura, and H. Ito, PI3K-Akt pathway: Its functions and alterations in human cancer, Apoptosis, vol.9, issue.6, pp.667-676, 2004.
DOI : 10.1023/B:APPT.0000045801.15585.dd

Y. Samuels, Z. Wang, A. Bardelli, N. Silliman, J. Ptak et al., High Frequency of Mutations of the PIK3CA Gene in Human Cancers, Science, vol.304, issue.5670, p.304554, 2004.
DOI : 10.1126/science.1096502

I. Campbell, S. Russell, D. Choong, K. Montgomery, M. Ciavarella et al., Mutation of the PIK3CA Gene in Ovarian and Breast Cancer, Cancer Research, vol.64, issue.21, pp.7678-7681, 2004.
DOI : 10.1158/0008-5472.CAN-04-2933

D. Byun, K. Cho, B. Ryu, M. Lee, J. Park et al., Frequent monoallelic deletion ofPTEN and its reciprocal associatioin withPIK3CA amplification in gastric carcinoma, International Journal of Cancer, vol.276, issue.3, pp.318-327, 2003.
DOI : 10.1002/ijc.10962

J. Pedrero, D. Carracedo, C. Pinto, A. Zapatero, J. Rodrigo et al., Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma, International Journal of Cancer, vol.6, issue.2, pp.242-248, 2005.
DOI : 10.1002/ijc.20711

Y. Ma, S. Wei, Y. Lin, J. Lung, T. Chang et al., PIK3CA as an oncogene in cervical cancer, Oncogene, vol.19, issue.23, pp.2739-2744, 2000.
DOI : 10.1038/sj.onc.1203597

I. Ali, L. Schriml, and M. Dean, Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity, JNCI Journal of the National Cancer Institute, vol.91, issue.22, pp.911922-1932, 1999.
DOI : 10.1093/jnci/91.22.1922

N. Chalhoub and S. Baker, PTEN and the PI3-Kinase Pathway in Cancer, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.127-150, 2009.
DOI : 10.1146/annurev.pathol.4.110807.092311

A. Bellacosa, D. De-feo, A. Godwin, D. Bell, J. Cheng et al., Molecular alterations of theAKT2 oncogene in ovarian and breast carcinomas, International Journal of Cancer, vol.54, issue.4, pp.280-285, 1995.
DOI : 10.1002/ijc.2910640412

Y. Min, J. Eom, J. Cheong, H. Maeng, J. Kim et al., Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable, Leukemia, vol.17, issue.5, pp.995-997, 2003.
DOI : 10.1038/sj.leu.2402874

J. Carpten, A. Faber, C. Horn, G. Donoho, S. Briggs et al., A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, vol.1, issue.7152, pp.448439-444, 2007.
DOI : 10.1038/nature05933

M. Jücker, K. Südel, S. Horn, M. Sickel, W. Wegner et al., Expression of a mutated form of the p85?? regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin???s lymphoma-derived cell line (CO), Leukemia, vol.16, issue.5, pp.894-901, 2002.
DOI : 10.1038/sj.leu.2402484

A. Philp, I. Campbell, C. Leet, E. Vincan, S. Rockman et al., The phosphatidylinositol 3?-kinase p85? gene is an oncogene in human ovarian and colon tumors, Cancer Res, issue.20, pp.617426-7429, 2001.

Y. Samuels and V. Velculescu, Oncogenic Mutations of PIK3CA in Human Cancers, Cell Cycle, vol.3, issue.10, pp.1221-1224, 2004.
DOI : 10.4161/cc.3.10.1164

Y. Samuels and K. Ericson, Oncogenic PI3K and its role in cancer, Current Opinion in Oncology, vol.18, issue.1, pp.77-82, 2006.
DOI : 10.1097/01.cco.0000198021.99347.b9

J. Abubaker, P. Bavi, S. Harbi, A. Siraj, F. Uddin et al., PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma, Leukemia, vol.64, issue.11, pp.2368-2370, 2007.
DOI : 10.1038/sj.leu.2404873

S. Uddin, A. Hussain, A. Siraj, P. Manogaran, A. et al., Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival, Blood, vol.108, issue.13, pp.4178-4186, 2006.
DOI : 10.1182/blood-2006-04-016907

M. Rudelius, S. Pittaluga, S. Nishizuka, T. Pham, F. Fend et al., Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma, Blood, vol.108, issue.5, pp.1668-1676, 2006.
DOI : 10.1182/blood-2006-04-015586

A. Psyrri, S. Papageorgiou, E. Liakata, A. Scorilas, D. Rontogianni et al., Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma, Clin Cancer Res, issue.18, pp.155724-5732, 2009.

H. Zha, M. Raffeld, L. Charboneau, S. Pittaluga, L. Kwak et al., Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray, Laboratory Investigation, vol.84, issue.2, pp.235-244, 2004.
DOI : 10.1038/labinvest.3700051

C. Gulmann, V. Espina, E. Petricoin, D. Longo, M. Santi et al., Proteomic Analysis of Apoptotic Pathways Reveals Prognostic Factors in Follicular Lymphoma, Clinical Cancer Research, vol.11, issue.16, pp.115847-5855, 2005.
DOI : 10.1158/1078-0432.CCR-05-0637

B. Lannutti, S. Meadows, S. Herman, A. Kashishian, B. Steiner et al., CAL-101, a p110?? selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability, Blood, vol.117, issue.2, pp.591-594, 2011.
DOI : 10.1182/blood-2010-03-275305

B. Kahl, J. Byrd, I. Flinn, N. Wagner-johnston, S. Spurgeon et al., Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110 ?, in patients with relapsed or refractory Non-Hodgkin lymphoma, p.1161777, 2010.

J. Castillo, M. Furman, and E. Winer, CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies, Expert Opinion on Investigational Drugs, vol.116, issue.21, pp.15-22
DOI : 10.1056/NEJMoa1002965

E. Jaffe, The 2008 WHO classification of lymphomas: implications for clinical practice and translational research, Hematology, vol.2009, issue.1, pp.523-531, 2009.
DOI : 10.1182/asheducation-2009.1.523

A. Gérard, M. Ghiotto, C. Fos, G. Guittard, D. Compagno et al., Dok-4 Is a Novel Negative Regulator of T Cell Activation, The Journal of Immunology, vol.182, issue.12, pp.1827681-7689, 2009.
DOI : 10.4049/jimmunol.0802203

A. Bader, S. Kang, L. Zhao, and P. Vogt, Oncogenic PI3K deregulates transcription and translation, Nature Reviews Cancer, vol.17, issue.12, pp.921-929, 2005.
DOI : 10.1038/nrc1753

C. Knobbe and G. Reifenberger, Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl-lnositol-3???-Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas, Brain Pathology, vol.84, issue.113 Pt, pp.507-518, 2003.
DOI : 10.1111/j.1750-3639.2003.tb00481.x

A. Bellacosa, C. Kumar, D. Cristofano, A. Testa, and J. , Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv Cancer Res, vol.94, pp.29-86, 2005.
DOI : 10.1016/S0065-230X(05)94002-5

P. Cornillet-lefebvre, W. Cuccuini, V. Bardet, J. Tamburini, L. Gillot et al., Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110?? mutations, Leukemia, vol.103, issue.2, pp.374-376, 2006.
DOI : 10.1038/sj.leu.2404054

D. Chantry, A. Vojtek, A. Kashishian, D. Holtzman, C. Wood et al., p110??, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes, Journal of Biological Chemistry, vol.272, issue.31, pp.110-27219236, 1997.
DOI : 10.1074/jbc.272.31.19236

E. Clayton, G. Bardi, S. Bell, D. Chantry, C. Downes et al., A Crucial Role for the p110?? Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation, The Journal of Experimental Medicine, vol.162, issue.6, pp.753-763, 2002.
DOI : 10.1093/emboj/17.2.414

G. Firaguay and J. Nunes, Analysis of Signaling Events by Dynamic Phosphoflow Cytometry, Science Signaling, vol.2, issue.86, p.3, 2009.
DOI : 10.1126/scisignal.286pl3

URL : https://hal.archives-ouvertes.fr/inserm-00408711

T. Gao, F. Furnari, and A. Newton, PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth, Molecular Cell, vol.18, issue.1, pp.13-24, 2005.
DOI : 10.1016/j.molcel.2005.03.008